Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.22 USD

29.22
24,234,574

-0.05 (-0.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (33 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

FDA Accepts Sanofi's (SNY) sBLA for Dupixent in Pediatric EoE

by Zacks Equity Research

If this filing is approved, Sanofi (SNY)/Regeneron's (REGN) Dupixent will be the first FDA-approved treatment for eosinophilic esophagitis in children aged 1 to 11. A final decision is expected in January.

Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Pfizer (PFE) closed at $32.98, marking a +0.89% move from the previous day.

CDC Recommends Pfizer's (PFE) RSV Jab to Protect Newborns

by Zacks Equity Research

Pfizer's (PFE) Abrysvo has been recommended by the CDC for preventing RSV in infants by immunizing pregnant women, during weeks 32-36 of pregnancy.

The Zacks Analyst Blog Highlights Pfizer, Merck and AstraZeneca

by Zacks Equity Research

Pfizer, Merck and AstraZeneca are part of the Zacks top Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: EU Nod to PFE's Litfulo, FDA Priority Tag to MRK Applications

by Kinjel Shah

The European Commission approves Pfizer's (PFE) Litfulo for severe alopecia areata. FDA gives priority tag to Merck's (MRK) supplemental applications for Welireg and Keytruda.

Pfizer (PFE) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed the most recent trading day at $33.99, moving +1.04% from the previous trading session.

Pfizer's (PFE) Alopecia Areata Drug Litfulo Receives EU Nod

by Zacks Equity Research

Pfizer (PFE) gets marketing authorization in the EU for Litfulo to treat adults and adolescent patients aged 12 years and older with severe alopecia areata.

The Zacks Analyst Blog Highlights Meta Platforms, Walmart, Johnson & Johnson, Pfizer and Morgan Stanley

by Zacks Equity Research

Meta Platforms, Walmart, Johnson & Johnson, Pfizer and Morgan Stanley are part of the Zacks top Analyst Blog.

Is Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for LVHD

Sheraz Mian headshot

Top Analyst Reports for Meta Platforms, Walmart & Johnson & Johnson

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Walmart Inc. (WMT) and Johnson & Johnson (JNJ).

Moderna (MRNA) Receives CHMP Nod for Updated COVID Vaccine

by Zacks Equity Research

Clinical data from studies on Moderna's (MRNA) updated COVID vaccine shows improved antibody responses against multiple circulating variants, including BA.2.86, EG.5 and FL.1.5.1 variants.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to Updated PFE, MRNA COVID Jabs, & More

by Kinjel Shah

The FDA authorizes Pfizer (PFE) and Moderna's (MRNA) updated mRNA-based COVID-19 vaccines. Novo Nordisk (NVO) conducts a two-for-one split of its shares and ADRs.

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Novo Nordisk (NVO) Announces Stock Split to Enhance Liquidity

by Zacks Equity Research

Novo Nordisk (NVO) conducts a two-for-one stock split. While this is already in effect at the stock exchange in Denmark, the ADRs listed on the NYSE will be split in the same ratio by next week.

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Pfizer (PFE) closed at $34.08, marking a -0.2% move from the previous day.

Altimmune (ALT) Rises 7% on Completing Dosing in Obesity Study

by Zacks Equity Research

Altimmune (ALT) completes the dosing of all patients in the mid-stage obesity study of pemvidutide. The company remains on track to announce top-line results in fourth-quarter 2023. The stock rises 7%.

The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Novavax

by Zacks Equity Research

Pfizer, BioNTech, Moderna and Novavax are included in this Analyst Blog.

Kinjel Shah headshot

FDA Approves Pfizer & Moderna's New COVID Booster Vaccines

by Kinjel Shah

Pfizer (PFE)/ BioNTech (BNTX), and Moderna's (MRNA) updated mRNA vaccines are now approved for individuals 12 years of age and older and are authorized under emergency use for individuals 6 months through 11 years of age.

Nurix (NRIX) Stock Increases 9% in a Month: Here's Why

by Zacks Equity Research

The upside in Nurix's (NRIX) shares can be attributed to the company's recently signed collaboration with Seagen (SGEN) to develop a new class of medicines for cancer.

Moderna (MRNA) Updated COVID Jab Effective Against Pirola Variant

by Zacks Equity Research

Clinical study data shows Moderna's (MRNA) updated COVID-19 vaccine generates a robust immune response against newer circulating variants, including Pirola and Eris.

Andrew Rocco headshot

Stocks on the Mend: A Mean Reversion Duo

by Andrew Rocco

September is starting in classic, historically weak form. However, if the market finds it's footing, two stocks have explosive, reversion to the mean potential.

Novo Nordisk (NVO) Launches Wegovy in UK Amid Supply Issues

by Zacks Equity Research

Novo Nordisk (NVO) announces the controlled and limited launch of Wegovy in the U.K. amid rising demand for weight loss treatment and supply constraints.

Novavax (NVAX) Stock Increases 9% in a Month: Here's Why

by Zacks Equity Research

This growth in Novavax (NVAX) is likely due to the rising COVID-19 infection cases in the United States. Management claims its updated vaccine is effective against the newly emerged virus variants.

Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Kinjel Shah headshot

Pharma Stock Roundup: J&J's New '23 View After Kenvue Separation, Regulatory Updates

by Kinjel Shah

J&J (JNJ) updates its financial guidance for 2023 after the final separation of Kenvue. Pfizer, BioNTech, Merck and AbbVie announce regulatory developments.